Not Medical Advice: This article is an educational review of scientific literature and does not account for individual health conditions. Always consult with healthcare professionals before making any health-related decisions.
When a meta-analysis of seven studies involving 3,607 older adults concluded that pharmacist-led deprescribing interventions improved medication burden indices without increased adverse events, well, that suggests a positive outcome [3]. Indeed, based on the findings, the process showed promising indications. The findings indicated improvements in medication burden indices without increased adverse events, which represents a favorable outcome. Pharmacists got in there, found those inappropriate medications, and helped stop them.
Then you look at the primary outcome: mean difference in total medications was -0.55 pills (with a confidence interval crossing zero), and the rate of effective deprescribing had a risk ratio of 1.85 that wasn't statistically significant [3]. Translation: we can't actually prove patients ended up taking fewer pills.
That gap between what felt like success and what we could actually count? That warrants further exploration, as it may offer insights into how deprescribing unfolds in the real world versus how it might be conceptualized in a textbook.
The Mortality Paradox
Consideration of outcomes that are highly relevant to patients may be a valuable starting point. An umbrella review of 110 randomized controlled trials indicated that medication reviews focused on deprescribing were associated with reduced mortality in community settings [1]. This represents a significant outcome that is widely sought after. The findings suggested fewer people died.
But the same interventions in hospital settings showed only modest effects [1]. Same concept, same medication review process, different building. The evidence quality was rated low due to heterogeneity and publication bias, and evidence on interventions remains limited and inconsistent [1].
Here's what's interesting: if deprescribing interventions are associated with reduced mortality in the community, one might anticipate a corresponding drop in pill count. That's supposedly the mechanism—fewer medications, fewer interactions, fewer adverse events, lower mortality. Yet the meta-analysis of pharmacist-led deprescribing couldn't demonstrate that first step [3].
So either mortality improved through something other than raw pill reduction, or the studies measuring pill counts weren't capturing the same population benefiting from reduced mortality.
What "Effective Deprescribing" Actually Measures
The meta-analysis defined effective deprescribing as discontinuation of at least one potentially inappropriate medication OR at least a 0.5 reduction in a drug burden index [3]. It is important to consider the use of "OR." You can actually succeed at effective deprescribing without stopping a single pill—just by reducing the burden score.
Drug burden indices assign weights to medications based on anticholinergic or sedative properties. Switching from a high-burden medication to a lower-burden alternative counts as improvement even if the total number stays the same. This outcome holds clinical significance. Research indicates that the use of a newer antihistamine rather than diphenhydramine may be associated with reduced fall risk.
But it's not fewer pills.
The pooled analysis found improvements in medication burden indices as a secondary outcome [3]. Improvements were observed in process measures. Medications identified as targets for deprescribing were being addressed. Yet when you count pills at the end, the numbers barely moved, and the confidence interval for total medication change ranged from removing 2.17 medications to adding 1.07 [3].
The Replacement Problem
Polypharmacy doesn't exist in isolation. Among older adults in Ethiopia, polypharmacy was significantly associated with potentially inappropriate prescribing (pooled prevalence 41%), potentially inappropriate medications (37%), and potentially harmful drug-drug interactions (55%) [2]. Hypertension showed an association with potentially inappropriate prescribing [2].
This last detail is noteworthy. When you're managing multiple chronic conditions—hypertension, diabetes, heart failure, COPD—each one comes with guideline-recommended therapy. Deprescribing a beta-blocker might be appropriate for one clinical reason, but then the patient's heart failure worsens and you're adding it back. Or you stop a statin during acute illness, and it never gets restarted because the patient had legitimate statin intolerance, but now they're on three other medications trying to control the same cardiovascular risk.
Depression is strongly associated with polypharmacy in older adults, with a pooled odds ratio of 2.49 [4]. Depression itself often requires pharmacotherapy, and the medications used to treat it contribute to the total count. You can't deprescribe your way out of undertreated depression.
Among older adults with frailty, polypharmacy rates ranged from 1.3% to 96.4% depending on the population studied, and potentially inappropriate medication prevalence ranged from 2.4% to 95.9% [6]. The ranges are absurd because frailty itself varies from 0.9% to 89.2% prevalence depending on how you define it [6]. But the pattern is consistent: frailty and high medication counts cluster together, and both are markers of complexity that make simple pill reduction an inadequate goal.
The Antihypertensive Test Case
One specific deprescribing intervention offers a cleaner test: stopping blood pressure medications in older adults. Four trials involving 2,173 participants compared antihypertensive deprescribing to usual care [5].
Results: no significant difference in all-cause mortality (risk ratio 1.02), cardiovascular mortality (1.11), hospitalizations (0.95), major cardiovascular events (1.09), or falls (1.00) [5]. The confidence intervals all crossed 1.0, meaning we can't rule out small harms or small benefits, but the point estimates cluster right around "no difference."
That's actually the ideal deprescribing outcome. It means you can safely stop these medications in selected older adults without increasing cardiovascular risk. But notice what it doesn't show: it doesn't show benefit from stopping. No reduction in falls despite stopping medications that cause orthostatic hypotension. No reduction in hospitalizations despite reducing pill burden.
The intervention was safe and feasible. It reduced medication exposure. It just didn't move the clinical outcomes we hoped it would move.
Where the Pills Actually Go
Back to the pharmacist-led interventions. Seven studies, five of them randomized controlled trials, implemented structured deprescribing protocols [3]. Pharmacists reviewed medications, identified potentially inappropriate prescriptions, communicated with physicians, and followed patients over time. The interventions varied in design and setting, which explains the 83.1% heterogeneity in medication count changes and 73.5% heterogeneity in deprescribing rates [3].
But here's the operational reality: a pharmacist recommends stopping medication A because it's potentially inappropriate. The physician agrees. The patient stops taking it. Two months later, the patient develops a symptom that medication A was preventing (even if inappropriately), or a new problem emerges that requires medication B, or the patient ends up in the hospital where a different physician starts medications C and D.
The deprescribing intervention counted as successful—medication A was inappropriate and got stopped. But the total count at final follow-up didn't change because the patient's medical complexity didn't change.
An umbrella review found that behavioral and mixed educational-behavioral interventions appeared most effective in reducing hospitalizations, particularly in community populations [1]. These weren't pure deprescribing interventions. They combined medication optimization with adherence support, patient education, and coordinated care. The medication count might not drop, but the medications being taken are more appropriate, better coordinated, and actually consumed as prescribed.
None of that shows up in a simple pill count.
The Measurement Gap
Adverse drug reactions and drug-drug interactions contribute substantially to hospitalizations and morbidity in multimorbid patients [7]. Polypharmacy is a recognized risk factor for falls [7]. These are the harms deprescribing aims to prevent.
Yet when studies of antihypertensive deprescribing found no significant difference in falls, and the umbrella review found no intervention significantly reduced fall risk [1], [5], we're left with a disconnect. If polypharmacy causes falls, and we reduce polypharmacy, falls should decrease. They didn't.
Three possibilities: the medications being deprescribed weren't the ones causing falls, the fall risk comes from frailty and comorbidity rather than medications per se, or the studies weren't large enough or long enough to detect the difference. The current evidence base remains limited and uncertain, as the antihypertensive deprescribing review notes [5].
What we can prove is that deprescribing doesn't increase mortality or cardiovascular events [5]. What we can't prove is that it reduces the total number of medications patients actually take over time, or that it prevents the adverse outcomes we're worried about [1], [3].
Management strategies include deprescribing protocols, electronic decision support systems, and interdisciplinary care [7]. All of these improve the process. Whether they change the outcome at the patient's pill organizer remains unclear.
π Bottom Line
Deprescribing works as a clinical process—pharmacists and physicians can identify inappropriate medications, safely discontinue them, and improve medication burden indices without increasing adverse events. In community settings, medication reviews even reduce mortality. But the evidence consistently fails to demonstrate significant reductions in total pill count, and most hard outcomes (falls, hospitalizations, cardiovascular events) show no significant benefit from deprescribing strategies.
This suggests the problem isn't simply "too many pills." It's wrong pills, poorly coordinated care, and underlying medical complexity that generates ongoing medication needs. Success means optimizing therapy and preventing harm, not hitting a target pill count. A patient taking eight appropriate, necessary medications is better off than one taking five inappropriate ones. The goal is better prescribing across the patient's trajectory, not a lower number at a single timepoint.
The disconnect between process measures and patient-relevant outcomes tells us we're measuring success in ways that don't fully capture whether patients actually experience less medication burden over time. Clinical trials can prove non-inferiority and safety. What they haven't proven is that deprescribing creates sustained reductions in the pill counts that patients see when they open their medication drawer.
π You May Also Like
References
[1] Valz G, Farina S, Porcelli M, et al. Polypharmacy management interventions in older adults: An umbrella review of meta-analyses of randomized controlled trials. Public health. 2026. PMID: 41349295
https://pubmed.ncbi.nlm.nih.gov/41349295/
[2] Yazie T, Alemu M, Zewdu W, et al. Prevalence of potentially inappropriate medication prescribing, inappropriate medication use, prescription omission and drug interactions among older adults in Ethiopia: a systematic review and meta-analysis. BMJ open. 2026. PMID: 41775477
https://pubmed.ncbi.nlm.nih.gov/41775477/
[3] Tesfaye Z, Horsa B, Yismaw M. Impact of pharmacist-led deprescribing interventions on medication related outcomes among older adults: a systematic review and meta-analysis. BMC geriatrics. 2026. PMID: 41514446
https://pubmed.ncbi.nlm.nih.gov/41514446/
[4] Wang Y, Tsai T, Chou H, et al. Association Between Depression and Polypharmacy in Older Adults-A Systematic Review and Meta-Analysis. Journal of general and family medicine. 2026. PMID: 41696732
https://pubmed.ncbi.nlm.nih.gov/41696732/
[5] Alsubaiei A, Alyahya S, Emara A, et al. Efficacy and safety of antihypertensive drugs deprescribing in older adults: A systematic review and meta-analysis of randomized controlled trials. International journal of cardiology. Cardiovasc.... 2026. PMID: 41550131
https://pubmed.ncbi.nlm.nih.gov/41550131/
[6] Sharma R, Sharma T, McCready-Branch B, et al. Medication Use by Older Adults with Frailty: A Scoping Review. Pharmacy (Basel, Switzerland). 2025. PMID: 41283631
https://pubmed.ncbi.nlm.nih.gov/41283631/
[7] S H, Tripathi S, Venuturumilli R, et al. Adverse Drug Reactions and Drug Interactions in Multimorbid Patients: A Review of Current Evidence. Cureus. 2025. PMID: 41450405
https://pubmed.ncbi.nlm.nih.gov/41450405/
π’ Strong Evidence
The vast majority of papers (10 out of 11) directly and specifically address 'Elderly Polypharmacy Management', including seven systematic reviews with meta-analyses of RCTs and one standalone RCT. This robust body of high-level interventional evidence is highly capable of providing concrete, quantified, and likely converging findings to meaningfully answer the driving question.
Educational Purpose: This article is a review of publicly available scientific literature and does not constitute medical advice, diagnosis, or treatment. Individual health situations vary greatly, and the content discussed here may not be appropriate for your specific circumstances.
Professional Consultation Required: Before making decisions about medications or health-related matters, always consult with qualified healthcare professionals (physicians, pharmacists, or other qualified healthcare providers). They can evaluate your complete medical history and current condition to provide personalized guidance.
No Conflicts of Interest: The author has no financial relationships with pharmaceutical companies or product manufacturers mentioned in this article. This content is provided independently for educational purposes.
Source-Based: All substantive claims are supported by peer-reviewed scientific literature or official clinical trial data. Readers are encouraged to verify original sources directly for comprehensive understanding.
AI-Assisted Content: This article was researched and written with AI assistance, then reviewed and edited by a licensed pharmacist. AI tools were used for literature search, data organization, and draft generation.
Keywords: #PolypharmacyManagement, #Deprescribing, #ElderlyMedication, #ClinicalPharmacy, #MedicationReview, #PatientSafety, #GeriatricPharmacotherapy, #InappropriatePrescribing
Last Updated: March 2026 | Evidence Base: Research published through 2026
Comments